Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747714 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL15093907 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL30200423 | 0.81 | TARBP2 (0.46) | NPSR1KDM4EALDH1A1RAB9ATSHR | |
| SCHEMBL14857925 | 0.81 | ALDH1A1 (0.35) | NPSR1ALDH1A1RAB9ALMNANPC1 | |
| SCHEMBL16030718 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL17513100 | 0.80 | NPSR1 (0.48) | NPSR1KDM4ESMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL16631730 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL31421969 | 0.80 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL26608356 | 0.79 | NOTUM (0.46) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL25361003 | 0.79 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4110460-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115485023-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2022-12-16 | — | — | CN | disclosed |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2022-10-18 | — | — | US | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2768830-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2766361-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055895-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055897-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | NPSR1 339/4885KDM4E 4053/4885ALDH1A1 230/4885 |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | NPSR1 4730/4885KDM4E 3047/4885ALDH1A1 4176/4885 |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | NPSR1 4769/4885KDM4E 2955/4885ALDH1A1 4319/4885 |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | NPSR1 4769/4885KDM4E 2955/4885ALDH1A1 4319/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | NPSR1 4769/4885KDM4E 2955/4885ALDH1A1 4319/4885 |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2A1, BCL2L1, BCL2L11 | NPSR1 4854/4885KDM4E 3275/4885ALDH1A1 4415/4885 |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | NPSR1 2006/4885KDM4E 3046/4885ALDH1A1 3559/4885 |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | NPSR1 412/4885KDM4E 1690/4885ALDH1A1 3214/4885 |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | NPSR1 4769/4885KDM4E 2955/4885ALDH1A1 4319/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | NPSR1 4769/4885KDM4E 2955/4885ALDH1A1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.